Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lysann Kroschwald"'
Autor:
Matthias C. Schulz, Stefan Holtzhausen, Berthold Nies, Sascha Heinemann, David Muallah, Lysann Kroschwald, Kristin Paetzold-Byhain, Günter Lauer, Philipp Sembdner
Publikováno v:
Journal of Personalized Medicine. 13:464
For sinus grafting, different methods and materials are available. One possible shortcoming of particulate bone grafts is either overfilling or augmenting the planned implant area insufficiently. To overcome this risk and to determine the implant pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18cbaef5f8102f8d2a4be4f65844c31d
https://doi.org/10.3390/jpm13030464
https://doi.org/10.3390/jpm13030464
Autor:
Meinolf Suttorp, Sonja Kroschwald, Anne Wiedenfeld, Martina Rauner, Lysann Kroschwald, Andrea Bauer, Stefan Beissert, Josephine T. Tauer
Publikováno v:
Oncology Letters.
Tyrosine kinase inhibitors (TKIs), such as imatinib (IMA) and nilotinib (NIL), are the cornerstone of chronic myeloid leukemia (CML) treatment via the blockade of the oncogenic BCR-ABL1 fusion protein. However, skeletal side effects are commonly obse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac16bba424b19acd073b0de027927d54
https://doi.org/10.3892/ol.2019.10518
https://doi.org/10.3892/ol.2019.10518
Autor:
Anna Ulmer, PaulaGeidel, Josephine T. Tauer, M Suttorp, Vera Girke, Bernadette A. S. Jäger, Lysann Kroschwald
Publikováno v:
Experimental Animal Models of Human Diseases-An Effective Therapeutic Strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a56aabbeda649db530024badc321925
http://www.intechopen.com/articles/show/title/studying-side-effects-of-tyrosine-kinase-inhibitors-in-a-juvenile-rat-model-with-focus-on-skeletal-r
http://www.intechopen.com/articles/show/title/studying-side-effects-of-tyrosine-kinase-inhibitors-in-a-juvenile-rat-model-with-focus-on-skeletal-r
Autor:
Claudia Günther, Josephine T. Tauer, Andrea Bauer, Lysann Kroschwald, Nick Zimmermann, Meinolf Suttorp
Publikováno v:
Molecular medicine reports. 17(1)
Prolonged treatment with tyrosine kinase inhibitors (TKI) including imatinib (IMA) or nilotinib (NIL), induces severe disturbances of bone metabolism in patients with chronic myeloid leukaemia. As vitamin D3 (VD3) is involved in the complex cycle of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e052e60b9af2016aa5f7bee6cd9acbc6
https://pubmed.ncbi.nlm.nih.gov/29115640
https://pubmed.ncbi.nlm.nih.gov/29115640